Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment – preliminary report
Open Access
- 1 January 2017
- journal article
- Published by Termedia Sp. z.o.o. in Clinical and Experimental Hepatology
- Vol. 4 (4) , 194-197
Abstract
Aim of the study : New interferon-free direct-acting antiviral (DAA) therapy has led to major progress in hepatitis C virus (HCV) treatment. Current outcomes are promising, especially in compensated cirrhosis. However, there are reports of accelerated hepatocellular carcinoma (HCC) recurrence...Keywords
This publication has 18 references indexed in Scilit:
- Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infectionJournal of Medical Virology, 2016
- Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without CirrhosisGastroenterology, 2015
- Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver DiseaseGastroenterology, 2015
- Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular CarcinomaAnnals of Internal Medicine, 2013
- Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver DiseaseGastroenterology, 2009
- Estimation of stage‐specific fibrosis progression rates in chronic hepatitis C virus infectionHepatology, 2008
- Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis CGastroenterology, 2005
- Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance☆Gastroenterology, 2004
- Natural history of chronic hepatitis CHepatology, 2002
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002